- **Record Q3 Results**: $12.5B revenue (+12% YoY), beating estimates by $200M
- **$10B AI Investment**: Accelerating enterprise AI adoption with Microsoft 365 Copilot (>100M users)
- **Margin Expansion**: 200+ basis point improvement in cloud gross margin
- **FY24 Guidance**: 10-12% revenue growth, 12-14% EPS growth (non-GAAP)
- **Key Risk**: $1.5B FX headwind in 2024


**【CEO Opening Remarks】**
- Highlighted Q3 revenue of $12.5B (+12% YoY), driven by cloud and AI solutions.
- Announced $10B+ investment in generative AI over next 5 years, targeting enterprise adoption.
- Emphasized margin expansion through cost optimization and higher-margin product mix.

**【CFO Financial Breakdown】**
- GAAP EPS: $2.87 (vs. $2.65 consensus)
- Free cash flow: $12.3B (up 15% YoY)
- Cloud revenue: $6.2B (+20% YoY), with Azure growth accelerating to 25%
- R&D spend: $6.5B (21% of revenue), up 15% YoY

**【Q&A Key Takeaways】**
- **AI Strategy**: Microsoft 365 Copilot adoption >100M users; enterprise contracts >$100M
- **Regulatory Risk**: Confident in compliance with EU AI Act; no material impact on operations
- **Currency Impact**: 2024 FX headwind ~$1.5B; hedging strategy to mitigate
- **FY24 Outlook**: Revenue +10-12%, EPS +12-14% (non-GAAP)


Regulus Therapeutics (RGLS)-11 Nov 22-2022 Q3 Earnings call transcript

Regulus Therapeutics (RGLS)-11 Aug 22-2022 Q2 Earnings call transcript

Regulus Therapeutics (RGLS)-13 May 22-2022 Q1 Earnings call transcript

Regulus Therapeutics (RGLS)-11 Mar 22-2021 Q4 Earnings call transcript

Regulus Therapeutics (RGLS)-11 Nov 21-2021 Q3 Earnings call transcript

Regulus Therapeutics (RGLS)-11 Aug 21-2021 Q2 Earnings call transcript

Regulus Therapeutics (RGLS)-14 May 21-2021 Q1 Earnings call transcript

Regulus Therapeutics (RGLS)-10 May 18-2018 Q1 Earnings call transcript

Regulus Therapeutics (RGLS)-7 Mar 18-2017 Q4 Earnings call transcript

Regulus Therapeutics (RGLS)-7 Nov 17-2017 Q3 Earnings call transcript

RGLS(Delisted)

RGLS fundamentals

Earnings Call

You can ask Aime